Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial

Samankaltaisia teoksia

• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
  Tekijä: Eustace, A, et al.
  Julkaistu: (2013)
• Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
  Tekijä: Irlam-Jones, J, et al.
  Julkaistu: (2016)
• A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
  Tekijä: Yang, L, et al.
  Julkaistu: (2017)
• A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
  Tekijä: Eustace, A, et al.
  Julkaistu: (2013)
• An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer
  Tekijä: Ord, J, et al.
  Julkaistu: (2007)